Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Joinn Laboratories(China)Co.,Ltd. (603127.SS)
Beijing, CN
Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.32% | -1.26% | +2.40% | +4.26% | +18.54% | +11.97% | +145.77% | +16.53% | -29.24% | +1,540.17% | +1,540.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-17.9% Q1'26: +10.0% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+300.0% ★ Q1'26: +540.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+38.8% ★ Q1'26: -76.4% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+20.5% ★ Q1'26: +81.1% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+6.1% ★ Q1'26: +15.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.5% Q1'26: -9.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.00× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 7 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
301.28M
est: 300.00M (+0.4%)
|
408.80M
est: 409.00M (0.0%)
|
639.38M
est: 593.92M (+7.7%)
|
1.08B
est: 1.02B (+5.5%)
|
1.52B
est: 1.53B (-0.8%)
|
2.27B
est: 2.21B (+2.5%)
|
2.38B
est: 2.21B (+7.4%)
|
2.02B
est: 2.06B (-1.9%)
|
1.66B
est: 1.63B (+1.8%)
|
1.93B
1.76B – 2.16B
+18.5% YoY
|
2.29B
1.90B – 2.59B
+18.5% YoY
|
2.86B
2.86B – 2.86B
+25.2% YoY
|
| EBITDA |
107.77M
est: 82.11M (+31.3%)
|
133.58M
est: 111.94M (+19.3%)
|
214.99M
est: 162.56M (+32.3%)
|
341.85M
est: 279.11M (+22.5%)
|
490.27M
est: 418.39M (+17.2%)
|
802.60M
est: 605.58M (+32.5%)
|
676.51M
est: 594.31M (+13.8%)
|
179.58M
est: 552.53M (-67.5%)
|
483.24M
est: 436.94M (+10.6%)
|
517.80M
471.38M – 581.02M
+18.5% YoY
|
613.58M
508.92M – 695.36M
+18.5% YoY
|
768.01M
767.75M – 768.26M
+25.2% YoY
|
| EBIT |
81.58M
est: 67.83M (+20.3%)
|
104.52M
est: 92.48M (+13.0%)
|
172.63M
est: 134.29M (+28.6%)
|
281.20M
est: 230.57M (+22.0%)
|
415.82M
est: 345.63M (+20.3%)
|
708.41M
est: 500.27M (+41.6%)
|
573.16M
est: 475.35M (+20.6%)
|
83.69M
est: 441.93M (-81.1%)
|
338.91M
est: 349.48M (-3.0%)
|
414.15M
377.03M – 464.72M
+18.5% YoY
|
490.76M
407.05M – 556.17M
+18.5% YoY
|
614.28M
614.07M – 614.48M
+25.2% YoY
|
| Net Income |
76.45M
est: 78.71M (-2.9%)
|
108.34M
est: 133.88M (-19.1%)
|
186.77M
est: 189.42M (-1.4%)
|
315.01M
est: 331.01M (-4.8%)
|
557.46M
est: 549.74M (+1.4%)
|
1.07B
est: 920.39M (+16.7%)
|
396.99M
est: 136.62M (+190.6%)
|
74.08M
est: 58.31M (+27.0%)
|
297.84M
est: 273.30M (+9.0%)
|
374.81M
48.78M – 555.50M
+37.1% YoY
|
463.34M
218.69M – 725.11M
+23.6% YoY
|
804.13M
719.81M – 899.77M
+73.6% YoY
|
| SGA |
57.60M
est: 48.65M (+18.4%)
|
83.41M
est: 66.33M (+25.7%)
|
107.66M
est: 96.32M (+11.8%)
|
221.54M
est: 165.38M (+34.0%)
|
272.13M
est: 247.91M (+9.8%)
|
317.88M
est: 358.82M (-11.4%)
|
304.87M
est: 299.92M (+1.6%)
|
317.06M
est: 278.84M (+13.7%)
|
120.09M
est: 220.51M (-45.5%)
|
261.31M
237.89M – 293.22M
+18.5% YoY
|
309.65M
256.83M – 350.92M
+18.5% YoY
|
387.58M
387.45M – 387.71M
+25.2% YoY
|
| EPS |
0.15
est: 0.11 (+41.2%)
|
0.17
est: 0.18 (-5.9%)
|
0.30
est: 0.26 (+18.3%)
|
0.51
est: 0.45 (+13.3%)
|
0.77
est: 0.74 (+3.8%)
|
1.44
est: 1.24 (+15.9%)
|
0.53
est: 0.18 (+187.2%)
|
0.10
est: 0.08 (+27.3%)
|
0.40
est: 0.37 (+8.6%)
|
0.54
0.07 – 0.75
+45.6% YoY
|
0.68
0.29 – 0.97
+27.4% YoY
|
1.08
0.97 – 1.21
+58.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.04% | 28.7K | 0.55% |
| 2 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 195.0K | 0.19% |
| 3 | Invesco FTSE All-World UCITS ETF FTWG.L | 0.01% | 251.7K | 0.15% |
| 4 | Invesco FTSE All-World UCITS ETF FWRA.SW | 0.01% | 252.2K | 0.15% |
| 5 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 169.6K | 0.17% |
| 6 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 169.6K | 0.17% |
| 7 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 17.4K | 0.40% |
| 8 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 350.0K | 0.06% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 67.3K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 29.8K | 0.48% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aishui Yu | Chief Financial Officer | — | female |
| Dalin Yao | Chief Scientific Officer | — | — |
| Dapeng Gao | GM, Secretary to the Board, Joint Company Secretary & Executive Director | — | male |
| Jingliang Gu | Vice GM, Head of Sales Department and Executive Director | — | male |
| Xi Luo | Executive Director | — | female |
| Yunxia Sun DCBT | Vice GM & Executive Director | — | — |
| Yuxia Feng | Founder & Chairman | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603127.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
